GCAN · Trafalgar International, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Oct 17, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Oct 17, 2025.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GCAN
this stock
Trafalgar International, Inc.
|
$297,021 | +206.7% | -92.5% | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +15.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.38B | -0.1% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | -0.8% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Oct 17, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GCAN | -30.8% | -8.9% | — | +4.6% | +206.7% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -31.3% | -10.2% | — | +1.9% | +194.2% |